Welcome to our dedicated page for CNS Pharmaceuticals news (Ticker: CNSP), a resource for investors and traders seeking the latest updates and insights on CNS Pharmaceuticals stock.
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) is a clinical-stage biopharmaceutical company developing anti-cancer drug candidates for primary and metastatic cancers of the brain and central nervous system. The CNSP news feed highlights the company’s announcements about its clinical programs, corporate developments, and interactions with the scientific and investment communities.
A central theme in CNS Pharmaceuticals’ news is the progress of its lead drug candidate, TPI 287. The company issues updates on clinical data, including Phase 1 results in glioblastoma patients treated with TPI 287 in combination with bevacizumab, and discusses the potential of TPI 287 to cross the blood-brain barrier and treat CNS tumors. Releases also describe the breadth of indications in which TPI 287 has been studied, from recurrent glioblastoma and pediatric neuroblastoma to metastatic melanoma and breast cancer metastatic to the brain.
News items also cover scientific visibility, such as acceptance of abstracts for poster presentation at the Society of Neuro-Oncology Annual Meeting. These abstracts, as described by the company, address topics like Berubicin in glioblastoma and pediatric diffuse midline glioma, as well as future evaluation of TPI 287 in CNS diseases. In addition, CNS Pharmaceuticals reports participation in investor conferences and virtual events, where management discusses its development strategy and corporate outlook.
Corporate and governance updates appear in the news as well, including announcements of a 1-for-12 reverse stock split and leadership changes, such as the planned transition of the chief executive officer role to Rami Levin. For investors and observers following CNSP, this news page provides a centralized view of the company’s disclosed milestones in neuro-oncology drug development, capital structure decisions, and executive leadership.
CNS Pharmaceuticals (NASDAQ:CNSP) issued a letter from newly appointed President and CEO Rami Levin outlining a strategic evaluation of the company on January 27, 2026. The CEO said the review covers the pipeline, development priorities, operations and capital allocation, with three guiding principles: Patients First, Pipeline Enrichment and Optimization, and Disciplined Value Creation. The company identified TPI 287 as its lead asset and core value driver and plans to refine clinical and regulatory strategies, prioritize indications, align with regulators and raise capital toward data and milestone achievements.
CNS Pharmaceuticals (NASDAQ:CNSP) announced a CEO transition: John Climaco has stepped down and Rami Levin, MBA, will become President & Chief Executive Officer effective January 1, 2026. Levin brings nearly 30 years of global biopharma experience across oncology, neurology, rare diseases, and cell & gene therapy and highlights include scaling organizations, raising capital, and advancing late‑stage programs. The release cites Levin's prior roles at Saniona, ImStem, Sobi, Merck Serono and a record of growing Sobi North American revenue from $46M to >$500M. CNS expects Levin to advance TPI 287 and strengthen commercial and development strategy.
CNS Pharmaceuticals (NASDAQ:CNSP) reported Q3 2025 results and a corporate update on November 17, 2025. Key financials: net loss $3.3M vs $5.6M year-ago, R&D $2.2M vs $4.2M, G&A $1.1M vs $1.4M, and cash $9.9M as of September 30, 2025. Management says cash is expected to fund operations into the second half of 2026. Lead program TPI 287 — an abeotaxane engineered for blood-brain barrier penetration — showed Phase 1 activity in GBM with 3 complete responses and 9 partial responses among 23 evaluable patients. The company plans FDA engagement on a potential Phase 2/registration study in early 2026.
CNS Pharmaceuticals (NASDAQ:CNSP) announced three abstracts accepted for poster presentation at the Society for Neuro-Oncology (SNO) 30th Annual Meeting, Nov 19-23, 2025, in Honolulu, HI.
All three posters will be presented by Sandra Silberman, MD, PhD, CNS chief medical officer: preliminary activity of berubicin against pediatric diffuse midline glioma (DMG) on Nov 21, 2025; planned Phase 2 evaluation of TPI 287 plus bevacizumab and other CNS indications on Nov 22, 2025; and primary randomized trial results comparing berubicin vs lomustine in glioblastoma after prior therapy on Nov 22, 2025.
CNS Pharmaceuticals (NASDAQ:CNSP), a biopharmaceutical company focused on developing treatments for brain and central nervous system cancers, will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025 in New York.
The company's presentation will be available via video webcast starting September 8, 2025, at 7:00 AM ET for registered attendees. Management will also conduct one-on-one meetings with qualified investors during the conference. The webcast recording will remain accessible on the company's website for 90 days after the event.
CNS Pharmaceuticals (NASDAQ:CNSP) has reported its Q2 2025 financial results and provided updates on its drug development programs. The company maintains a strong cash position of $12.1 million, expected to sustain operations into H2 2026.
The company's lead program, TPI 287, an abeotaxane designed to cross the blood-brain barrier, showed promising results in Phase 1 trials for glioblastoma multiforme (GBM), achieving 3 Complete Responses and 9 Partial Responses out of 23 evaluable patients when combined with bevacizumab. CNS plans to initiate a Phase 2 study in H1 2026 and engage with FDA on study design in 2025.
For Q2 2025, CNS reported a net loss of $2.4 million, slightly improved from $2.5 million in Q2 2024, with R&D expenses of $1.2 million and reduced G&A expenses of $1.2 million.
CNS Pharmaceuticals (NASDAQ:CNSP), a biopharmaceutical company focused on developing treatments for brain and central nervous system cancers, will participate in the upcoming Webull Financial Corporate Connect Webinar Series: Biotech/MedTech. The virtual presentation will be delivered by CEO John Climaco on Tuesday, August 19, 2025, at 2:40 PM ET.
CNS Pharmaceuticals (NASDAQ:CNSP), a biopharmaceutical company focused on developing treatments for brain and central nervous system cancers, announced its participation in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference. CEO John Climaco presented at the event, sharing insights about his leadership journey and passion for the company's development programs.
The presentation is now available for viewing on virtualinvestorco.com and the Events page in the Investors section of cnspharma.com.
CNS Pharmaceuticals (NASDAQ:CNSP) has announced a 1-for-12 reverse stock split of its common stock, effective July 22, 2025. The biopharmaceutical company's stock will continue trading on the Nasdaq Capital Market under the same symbol "CNSP" but with a new CUSIP number: 18978H508.
Under this reverse split, every 12 shares will be automatically combined into one share, with proportional adjustments made to outstanding warrants and equity-based awards. The company's authorized shares will be reduced to 25 million, while maintaining a par value of $0.001 per share. Stockholders entitled to fractional shares will receive cash payments instead.
CNS Pharmaceuticals (NASDAQ:CNSP), a biopharmaceutical company focused on developing treatments for brain and central nervous system cancers, announced CEO John Climaco's participation in a Virtual Investor CEO Connect segment. During the presentation, Climaco discussed the company's lead program TPI 287 and shared insights from the Longwood Healthcare Leaders Spring 2025 Meeting in Cambridge, MA.